Glycopyrrolate for treating childhood asthma

A technology of glycopyrronium bromide and children's asthma, which is applied in the field of children's asthma treatment and can solve problems such as systemic side effects and insufficient dosage

Inactive Publication Date: 2007-05-30
SOSEI R&D LTD
View PDF2 Cites 10 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

There are no drugs that have a reliable, adequate effect on typical inhalation in children; they are either underdosed or risk undesired systemic side effects

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Glycopyrrolate for treating childhood asthma
  • Glycopyrrolate for treating childhood asthma
  • Glycopyrrolate for treating childhood asthma

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0061] A 75:25 mass ratio mixture of micronized glycopyrronium bromide and magnesium stearate (total mass approximately 1 g) was placed on top of 100 g of 2 mm diameter stainless steel balls in a ball mill. Grind volume was about 58.8ml. Add 5 ml of cyclohexane to wet the above mixture. The ball mill was sealed and secured in a Retsch S100 centrifuge. It was then centrifuged at 500 rpm for a total of 240 minutes. A small sample (approximately 5-10 mg) of the wet powder was removed from the ball mill every 60 minutes. The samples were vacuum dried in an oven at 37°C.

[0062] The resulting formulations were assayed. The method and results are documented below:

[0063] Primary Research in COPD - Research Criteria

[0064] Single-dose, double-blind, placebo-controlled ascending-dose study

[0065] 4 treatment days: randomly dosed in sequence of 60→120→240→480 μg with placebo

[0066] A total of 8 patients (1 withdrew midway)

[0067] COPD (FEV1; FVC1 <70%)

[0068] to ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
Login to view more

Abstract

Glycopyrrolate or an analogue thereof is useful for the treatment of childhood asthma.

Description

field of invention [0001] The present invention relates to the treatment of children's asthma. Background of the invention [0002] Glycopyrrolate has been known for many years to be a potent antimuscarinic agent. It has been used for several indications and delivered by many different routes. Recently, it has been used as an injection to reduce secretion during anesthesia and as an oral product for the treatment of gastric ulcers. One of the earliest indications of its use in airway diseases was in 1984, where it was shown to have a marked effect on bronchiectasis. Since then, many studies have been done to prove its potential utility. [0003] Schroeckens tein et al., J. Allergy Clin. Immunol., 1988;82(1):115-119 disclose the use of an aerosol formulation of glycopyrronium bromide for the treatment of asthma. A single metered dose of aerosol glycopyrronium bromide achieved bronchodilation over a 12-hour period. [0004] Leckie et al., Exp.Opin.Invest.Drugs, 2000;9(1):...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61P11/06A61K31/465A61K31/00A61K31/352A61K31/40A61K31/439
CPCA61K31/00A61K31/40A61K31/439A61K31/352A61K31/465A61P11/06A61P37/08A61P43/00A61K2300/00A61K31/35
Inventor S·斯内普R·M·班尼斯特
Owner SOSEI R&D LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap